Clostridium
difficile
difficile
0
Clinically proven probiotic formulas. Discover the double-blind, randomized, controlled studies that demonstrate the efficacy of our products.
Clostridium difficile is a bacterium that normally resides harmlessly in the intestines of about 5% of the population. Following antibiotic treatment, the bacterial colonization in the intestines decreases, which promotes the proliferation of C. difficile. Once established, the bacteria produce toxins that can damage the intestine and cause diarrhea.
Clostridium difficile-associated diarrhea (CDAD) represents the leading cause of nosocomial infectious diarrhea.
Generally, affected individuals recover with antibiotic treatment, although research estimates that initial treatment fails in more than 20% of patients. Individuals undergoing antibiotic therapy are 7 to 10 times more likely to suffer from the infection.
Individuals in hospital settings or nursing homes are an at-risk population. Blood, mucus, or pus may also be found in the stool.
Broad-spectrum antibiotics act against a large number of bacteria without distinguishing between pathogenic bacteria and the beneficial bacteria residing in the intestinal flora. The resulting intestinal bacterial imbalance can lead to antibiotic-associated diarrhea (AAD).
Several studies have confirmed the efficacy of the probiotic yeast Saccharomyces boulardii in preventive treatment. This probiotic cannot be affected by antibiotics and helps restore the intestinal flora.
The beneficial effect was also reproduced in a randomized, double-blind controlled trial with 269 children aged 6 months to 14 years. The Probaclac Medic formula contains 5 billion active cells per capsule.
Recommended for preventing antibiotic-associated diarrhea, Lactobacillus rhamnosus GG significantly reduces the risk of developing antibiotic-associated diarrhea.
Infectious diarrheas are acute diarrheas. The WHO defines them as the passage of at least 3 loose to liquid stools per day for less than 2 weeks. Studies suggest that intestinal balance can be restored through rehydration and probiotic supplementation.
Clinical data on GG has proven its ability to reduce the incidence and duration of diarrhea episodes caused by viral or bacterial infections.
The vaginal flora is composed of a collection of microorganisms including a very large number of lactobacilli bacteria, called the Döderlein flora, which represents approximately 95% of the vaginal ecosystem. The beneficial bacteria form a protective biofilm on the vaginal mucosa.
The protective effect of lactobacilli involves various actions: they inhibit the growth of pathogenic bacteria by secreting a variety of substances and they interfere with their adhesion to vaginal epithelial cells.
The Probaclac Vaginal formula contains 8 billion bacteria from 3 different strains and helps regulate the Döderlein flora by repopulating it.
Bacterial vaginosis is an imbalance that can be caused by the proliferation of bacteria such as Gardnerella vaginalis or Prevotella. This change involves an increase in the normally acidic vaginal pH. This infection is asymptomatic in half of the women affected.
L. Plantarum Rosella is a unique strain isolated from a healthy vaginal flora, supported by comprehensive mechanistic and clinical evidence. Studied in more than 800 women across 6 clinical studies, it demonstrates its efficacy in maintaining optimal vaginal balance and managing recurrent vulvovaginal candidiasis (rVVC).
This strain is derived from a healthy human vaginal flora. The data documents both the maintenance of vaginal balance, recurrent vulvovaginal candidiasis, and the improvement of symptoms observed after treatment.
This strain demonstrates strong inhibitory activity against E. coli and K. pneumoniae, and intermediate activity against P. mirabilis. These bacteria are involved in several urinary and vaginal infections.
Study of 30 women with bacterial or fungal vaginitis, 6 days of intake followed by 9 days of follow-up.
After oral fluconazole pre-treatment, three monthly cycles at the end of the menstrual period.
Observed in the De Seta 2014 study, versus 68% in the comparator group.
After 90 days, versus 40% in the comparator group.
In the Cianci 2016 study, versus 47.8% in the control group.
Health claims in Canada: Reduces signs of vulvovaginal candidiasis (VVC). Helps treat recurrent vulvovaginal candidiasis (rVVC)*
*In combination with antifungal treatment
Lacticaseibacillus paracasei HA-196 is a beneficial bacterium naturally found in the mouth and intestines. It produces lactic acid, helping to lower digestive pH and curb the growth of harmful bacteria. Its ability to adhere to colonic epithelial cells gives it a competitive advantage against pathogens.
This section captures the spirit of the provided summary boards, but with charts, cards, and layouts entirely redesigned for the Probaclac brand.
Participants with IBS-C, IBS-D, or IBS-M subtypes. The randomized, double-blind, placebo-controlled study tracked changes in digestive symptoms and quality of life.
Two dimensions stand out at week 8: emotional well-being and social functioning.
Simplified reading of IBS-D and IBS-C subgroups between baseline, week 4, and week 8.
A significant decrease after 8 weeks versus placebo.
Accompanied by a reduction in laxative use.
Emotional well-being and social functioning stand out clearly.
Demonstrated in vitro antimicrobial activity against E. coli, Salmonella typhimurium, Listeria monocytogenes, Clostridium difficile, Staphylococcus aureus MRSA, and Klebsiella pneumoniae. HA-196 also produces hydrogen peroxide, inhibiting pathogen growth.
Market data: 25% of Canadian consumers suffer from irritable bowel syndrome at least occasionally. Only 42% report being satisfied with their digestive health in 2024, compared to 61% in 2022. 45% would find a supplement bearing the claim "relieves IBS symptoms" appealing.
Health claim in Canada: Clinically proven to reduce discomfort associated with irritable bowel syndrome. For diarrhea (IBS-D): reduces stool frequency by 21%. For constipation (IBS-C): increases stool frequency by 33%. 1 capsule per day, 10 billion CFU.
Probaclac probiotic strains survive without enteric coating at pH 3.
Once consumed, probiotics follow the natural path of the digestive tract. Passing through the mouth and then the esophagus, probiotics reach the stomach, a highly acidic environment when empty. Its acidity level varies: on an empty stomach, the pH is approximately 1, and around 6 when full.
The alkalinization of the stomach when it contains nutrients is the reason why it is preferable to take probiotics with food. The number of active bacteria can be affected in an overly acidic environment.
To ensure product efficacy, manufacturers must demonstrate that their probiotic strains can withstand a pH of 3. All Probaclac strains are capable of withstanding this acidity — bacterial viability is assured all the way to the intestines. No enteric coating is needed.
Lactobacillus strains are naturally found in the stomach — the journey therefore presents an opportunity to repopulate this flora.
